Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ABEO

Abeona Therapeutics Inc

Feb 13 • 04:00PM ET

5.01

+0.02 0.40 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN QURE SRPT SGMO BLUE CLGN ADVM FATE VYGR NTLA

| Held by: VTI IWM VXF SURI IWO VTWO FESM IWC ITOT EES

Index	RUT	P/E	4.30	EPS (ttm)	1.17	Insider Own	10.28%	Shs Outstand	52.40M	Perf Week	-2.34%
Market Cap	271.50M	Forward P/E	-	EPS next Y	-0.14	Insider Trans	-5.48%	Shs Float	48.62M	Perf Month	-3.47%
Enterprise Value	88.15M	PEG	-	EPS next Q	-0.35	Inst Own	59.12%	Short Float	29.48%	Perf Quarter	1.42%
Income	82.35M	P/S	678.75	EPS this Y	176.77%	Inst Trans	7.32%	Short Ratio	10.63	Perf Half Y	-30.71%
Sales	0.40M	P/B	1.53	EPS next Y	-111.93%	ROA	46.83%	Short Interest	14.33M	Perf YTD	-4.93%
Book/sh	3.27	P/C	1.31	EPS next 5Y	-	ROE	75.90%	52W High	7.54 -33.56%	Perf Year	-15.51%
Cash/sh	3.83	P/FCF	-	EPS past 3/5Y	58.40% 47.21%	ROIC	44.19%	52W Low	3.93 27.39%	Perf 3Y	104.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-858.75%	Volatility	3.46% 4.96%	Perf 5Y	-93.23%
Dividend TTM	-	EV/Sales	220.38	EPS Y/Y TTM	168.08%	Oper. Margin	-20802.25%	ATR (14)	0.23	Perf 10Y	-91.65%
Dividend Ex-Date	-	Quick Ratio	9.53	Sales Y/Y TTM	-100.00%	Profit Margin	20587.50%	RSI (14)	46.13	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.74	EPS Q/Q	84.88%	SMA20	-2.29%	Beta	1.13	Target Price	21.75
Payout	-	Debt/Eq	0.14	Sales Q/Q	-	SMA50	-2.96%	Rel Volume	0.32	Prev Close	4.99
Employees	136	LT Debt/Eq	0.09	Earnings	Nov 12 BMO	SMA200	-12.00%	Avg Volume	1.35M	Price	5.01
IPO	Sep 19, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	64.54% -100.00%	Trades		Volume	437,159	Change	0.40%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Resumed	Oppenheimer	Outperform	$19
Mar-05-25	Initiated	Oppenheimer	Outperform	$16
Jul-03-24	Initiated	H.C. Wainwright	Buy	$15
May-30-24	Initiated	Stifel	Buy	$21
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$4
Sep-18-20	Initiated	B. Riley FBR	Buy	$5
Feb-10-20	Initiated	SVB Leerink	Outperform	$6
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral	$2 → $4
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$29 → $2
Jul-26-19	Downgrade	Mizuho	Buy → Neutral	$17 → $4
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy	$17
Jun-05-18	Initiated	Seaport Global Securities	Buy	$29
Nov-08-17	Initiated	SunTrust	Buy	$26
Oct-16-17	Reiterated	H.C. Wainwright	Buy	$20 → $30
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight	$21 → $34
Oct-10-17	Initiated	Citigroup	Buy	$32
Oct-05-17	Reiterated	Maxim Group	Buy	$17 → $35
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$23

Show Previous Ratings

Feb-14-26 05:00AM	Netflix Is Casting a Light on a Rare Disease. Pearl Jam's Frontman Is Raising Cash to Cure It. (Barrons.com)
Feb-09-26 10:04AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-15-25 07:30AM	Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer (GlobeNewswire) -5.22%
Dec-11-25 07:30AM	Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in Texas (GlobeNewswire)
07:30AM	Loading…
Dec-08-25 07:30AM	Abeona Therapeutics Announces First Patient Treatment with ZEVASKYN Gene Therapy (GlobeNewswire) +5.34%
Dec-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.72%
Nov-12-25 04:01PM	Abeona Therapeutics Inc (ABEO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +18.47% -8.30%
11:37AM	Here's Why Abeona Therapeutics Popped Higher Today (Motley Fool)
07:40AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Nov-07-25 07:30AM	Abeona Therapeutics Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation (GlobeNewswire)
Nov-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-25 10:45AM	Abeona Therapeutics Announces Permanent J-Code for ZEVASKYN (prademagene zamikeracel) (GlobeNewswire)
Oct-20-25 08:30AM	Abeona Therapeutics Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs (GlobeNewswire)
07:30AM	Loading…
Oct-13-25 07:30AM	Abeona Therapeutics Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program (GlobeNewswire)
Oct-08-25 07:30AM	Abeona Therapeutics and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN Gene Therapy (GlobeNewswire) +5.52%
Oct-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-25 10:18AM	Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor? (Zacks)
Sep-08-25 08:28AM	Should You Invest in Abeona Therapeutics (ABEO)? (Insider Monkey)
Sep-02-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-29-25 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 07:38AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +10.21%
07:30AM	Abeona Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Aug-11-25 06:19AM	Cell Sheet-based Gene Therapy Market Analysis and Forecast, 2025-2035 \| Abeona Therapeutics, CellSeed, J-TEC, and Holostem Lead with First-in-Class Therapies and Strong Commercialization Strategies (GlobeNewswire)
Aug-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-25 11:40PM	Abeona Therapeutics, AscellaHealth Partner for Commercialization of ZEVASKYN Gene Therapy (Insider Monkey) -6.32%
Jul-29-25 10:00AM	AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients (GlobeNewswire)
Jul-15-25 07:30AM	ZEVASKYN Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area (GlobeNewswire)
Jul-14-25 07:00AM	Bio-Techne's Simple Western Technology Utilized in Recent FDA Approval of ZEVASKYN Cell-Based Gene Therapy (PR Newswire)
07:30AM	Loading…
Jul-02-25 07:30AM	Abeona Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million (GlobeNewswire) +5.39%
Jul-01-25 07:30AM	Abeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy (GlobeNewswire)
07:15AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-25 07:30AM	Abeona Therapeutics added to Membership of U.S. Small-cap Russell 2000 Index and Broad-market Russell 3000 Index (GlobeNewswire)
Jun-24-25 07:30AM	Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL Study Data in Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire)
Jun-02-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-25 08:46AM	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 07:38AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +7.42%
07:30AM	Abeona Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
May-14-25 08:07AM	UPDATE -- Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
May-13-25 07:21AM	Abeona secures cash runway with $155m priority review voucher sale (Pharmaceutical Technology)
May-12-25 07:30AM	Abeona Therapeutics Enters into Agreement to Sell Priority Review Voucher for $155 Million (GlobeNewswire) +6.26%
04:38AM	Abeona sells speedy drug review voucher for $155M (BioPharma Dive)
May-07-25 04:59PM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.51%
Apr-30-25 07:16AM	FDA approves Abeonas $3.1m cell therapy for rare skin disease (Pharmaceutical Technology) +23.77%
Apr-29-25 03:06PM	Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy (Benzinga)
06:00AM	U.S. FDA Approves ZEVASKYN (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Apr-27-25 08:30AM	Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken + (Seeking Alpha)
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha)
Apr-14-25 07:11AM	Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside (Seeking Alpha) +7.61%
Apr-12-25 11:39AM	Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher (Seeking Alpha)
Apr-06-25 08:38AM	Krystal Biotech: Some Uncertainty, Some Value (Seeking Alpha)
Apr-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.51%
Mar-21-25 03:02AM	Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
12:41AM	Q4 2024 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 03:21PM	Abeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparations (SeekingAlpha)
03:20PM	Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:30AM	Abeona Therapeutics Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans (GlobeNewswire)
Mar-04-25 09:00AM	Abeona Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
07:46AM	Abeona Therapeutics announces new employee inducement grants (TipRanks)
Mar-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESS Newswire) +6.30%
Nov-15-24 02:06AM	Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-14-24 07:42AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
Nov-12-24 07:30AM	Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire) -5.05%
Nov-04-24 07:30AM	Abeona Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire)
Nov-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-29-24 07:30AM	Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration (GlobeNewswire)
Oct-09-24 06:13PM	Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
Oct-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-24 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-24 07:30AM	Abeona Therapeutics Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors (GlobeNewswire)
Aug-13-24 07:30AM	Abeona Therapeutics Announces Favorable Medicare Reimbursement Decisions for Pz-cel (GlobeNewswire)
Aug-12-24 07:37AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +11.99%
07:30AM	Abeona Therapeutics Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission (GlobeNewswire)
Aug-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-11-24 07:30AM	Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications (GlobeNewswire)
Jul-08-24 07:30AM	Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum (GlobeNewswire) +5.73%
Jun-21-24 03:08AM	Insider Sale: Director Christine Silverstein Sells Shares of Abeona Therapeutics Inc (ABEO) (GuruFocus.com)
Jun-03-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 07:30AM	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 03:01AM	Abeona Therapeutics Inc (ABEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ... (GuruFocus.com)
02:17AM	Q1 2024 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-24 12:53PM	ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +12.14%
07:43AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress (GlobeNewswire)
May-07-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-03-24 11:19AM	Abeona Therapeutics Prices $75 Million Securities Offering; Shares Rise (MT Newswires) +13.02%
07:30AM	Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Apr-23-24 02:04PM	Top Midday Decliners (MT Newswires) -53.67%
08:53AM	Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today? (InvestorPlace)
07:39AM	Top Premarket Decliners (MT Newswires)
07:09AM	FDA rejects Abeona cell therapy, asks for more manufacturing data (BioPharma Dive)

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Silverstein Christine Berni	Director	Feb 02 '26	Proposed Sale	5.09	20,070	102,168		Feb 09 04:01 PM
Silverstein Christine Berni	Director	Feb 02 '26	Sale	5.09	20,070	102,168	137,722	Feb 04 04:30 PM
Wuchterl Donald A.	Director	Feb 02 '26	Sale	5.09	14,814	75,412	167,935	Feb 02 06:59 PM
Crombez Eric	Director	Feb 02 '26	Sale	5.09	16,284	82,895	63,456	Feb 02 06:55 PM
Wuchterl Donald A.	Director	Feb 02 '26	Proposed Sale	5.09	14,814	75,412		Feb 02 04:58 PM
Crombez Eric	Director	Feb 02 '26	Proposed Sale	5.09	16,284	82,886		Feb 02 04:43 PM
Alvino Mark	Director	Feb 02 '26	Proposed Sale	5.09	2,000	10,180		Feb 02 04:40 PM
Alland Leila	Director	Feb 02 '26	Proposed Sale	5.09	18,065	91,962		Feb 02 04:39 PM
Alland Leila	Director	Feb 02 '26	Sale	5.09	18,065	91,962	173,614	Feb 02 04:30 PM
Alvino Mark	Director	Feb 02 '26	Sale	5.09	2,000	10,181	84,065	Feb 02 04:30 PM
Vasanthavada Madhav	Chief Commercial Officer	Jan 22 '26	Sale	5.29	12,610	66,658	318,619	Jan 26 04:35 PM
Vazzano Joseph Walter	Chief Financial Officer	Jan 22 '26	Sale	5.33	18,666	99,507	568,560	Jan 22 08:34 PM
Seshadri Vishwas	Chief Executive Officer	Jan 22 '26	Sale	5.33	69,832	372,267	1,460,408	Jan 22 08:33 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Jan 22 '26	Sale	5.33	13,578	72,383	451,134	Jan 22 08:33 PM
Vasanthavada Madhav	Officer	Jan 22 '26	Proposed Sale	5.29	12,610	66,658		Jan 22 04:10 PM
Vazzano Joseph Walter	Officer	Jan 22 '26	Proposed Sale	5.33	18,666	99,507		Jan 22 04:09 PM
O'Malley Brendan M.	Officer	Jan 22 '26	Proposed Sale	5.39	13,578	73,233		Jan 22 04:09 PM
Seshadri Vishwas	Officer	Jan 22 '26	Proposed Sale	5.33	69,832	372,267		Jan 22 04:08 PM
Alvino Mark	Director	Jan 21 '26	Sale	5.23	13,500	70,574	48,752	Jan 21 04:30 PM
Alvino Mark	Director	Jan 21 '26	Proposed Sale	5.23	13,500	70,574		Jan 21 04:10 PM
Seshadri Vishwas	Chief Executive Officer	Dec 29 '25	Sale	5.31	25,000	132,740	1,164,818	Dec 29 04:30 PM
Seshadri Vishwas	Officer	Dec 29 '25	Proposed Sale	5.31	25,000	132,695		Dec 29 04:00 PM
Alvino Mark	Director	Nov 13 '25	Sale	4.74	15,000	71,168	62,252	Nov 14 04:30 PM
Alvino Mark	Director	Nov 13 '25	Proposed Sale	4.74	15,000	71,168		Nov 13 04:06 PM
Seshadri Vishwas	Chief Executive Officer	Oct 16 '25	Sale	5.49	249	1,366	1,189,818	Oct 16 04:15 PM
Seshadri Vishwas	Officer	Oct 16 '25	Proposed Sale	5.49	249	1,366		Oct 16 04:09 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Sep 29 '25	Sale	5.39	9,366	50,516	350,763	Oct 01 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Sep 30 '25	Sale	5.24	25,000	130,930	1,190,067	Oct 01 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Sep 29 '25	Sale	5.39	19,274	103,954	1,215,067	Oct 01 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Sep 29 '25	Sale	5.39	9,035	48,730	453,631	Oct 01 04:30 PM
Seshadri Vishwas	Officer	Sep 29 '25	Proposed Sale	5.39	44,274	238,792		Sep 29 04:54 PM
O'Malley Brendan M.	Officer	Sep 29 '25	Proposed Sale	5.39	9,366	50,516		Sep 29 04:44 PM
Vazzano Joseph Walter	Officer	Sep 29 '25	Proposed Sale	5.39	9,366	50,516		Sep 29 04:31 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Sep 22 '25	Sale	5.43	688	3,736	360,129	Sep 22 07:49 PM
O'Malley Brendan M.	Officer	Sep 22 '25	Proposed Sale	5.86	17,376	101,749		Sep 22 04:23 PM
Crombez Eric	Director	Aug 14 '25	Sale	6.93	4,718	32,683	42,427	Aug 15 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Aug 15 '25	Sale	7.36	15,000	110,358	462,666	Aug 15 04:30 PM
Vazzano Joseph Walter	Officer	Aug 15 '25	Proposed Sale	7.36	15,000	110,358		Aug 15 04:15 PM
Vazzano Joseph Walter	Chief Financial Officer	Jul 22 '25	Sale	6.64	1,502	9,975	477,666	Jul 22 04:15 PM
Vazzano Joseph Walter	Officer	Jul 22 '25	Proposed Sale	6.64	1,502	9,975		Jul 22 04:11 PM
Silverstein Christine Berni	Director	Jul 09 '25	Sale	5.86	13,093	76,669	120,479	Jul 10 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Jul 09 '25	Sale	5.86	69,420	406,503	1,234,341	Jul 10 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Jul 09 '25	Sale	5.86	25,411	148,799	479,168	Jul 10 04:30 PM
Wuchterl Donald A.	Director	Jul 08 '25	Sale	5.82	5,176	30,147	145,436	Jul 10 04:30 PM
Charles Faith L.	Director	Jul 09 '25	Sale	5.86	10,738	62,879	139,094	Jul 10 04:30 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Jul 09 '25	Sale	5.86	17,428	102,053	360,817	Jul 10 04:30 PM
Alvino Mark	Director	Jul 09 '25	Sale	5.86	13,093	76,669	77,252	Jul 10 04:30 PM
Vazzano Joseph Walter	Officer	Jul 09 '25	Proposed Sale	5.86	25,335	148,354		Jul 09 04:55 PM
Seshadri Vishwas	Officer	Jul 09 '25	Proposed Sale	5.86	69,215	405,302		Jul 09 04:52 PM
O'Malley Brendan M.	Officer	Jul 09 '25	Proposed Sale	5.86	17,376	101,749		Jul 09 04:48 PM
Charles Faith L.	Director	Jul 09 '25	Proposed Sale	5.86	10,706	62,691		Jul 09 04:45 PM
Silverstein Christine Berni	Director	Jul 09 '25	Proposed Sale	5.86	13,054	76,440		Jul 09 04:40 PM
Alvino Mark	Director	Jul 09 '25	Proposed Sale	5.86	13,054	76,440		Jul 09 04:36 PM
Wuchterl Donald A.	Director	Jul 08 '25	Proposed Sale	5.82	5,176	30,147		Jul 08 04:06 PM
Vazzano Joseph Walter	Chief Financial Officer	Jun 06 '25	Sale	6.76	17,795	120,294	491,246	Jun 06 06:04 PM
Seshadri Vishwas	Chief Executive Officer	Jun 06 '25	Sale	6.76	50,676	342,570	1,303,761	Jun 06 06:00 PM
O'Malley Brendan M.	SVP, General Counsel	Jun 06 '25	Sale	6.76	10,470	70,777	378,245	Jun 06 05:56 PM
Vazzano Joseph Walter	Officer	Jun 06 '25	Proposed Sale	6.76	17,795	120,314		Jun 06 04:13 PM
O'Malley Brendan M.	Director	Jun 06 '25	Proposed Sale	6.76	10,470	70,789		Jun 06 04:12 PM
Seshadri Vishwas	Officer	Jun 06 '25	Proposed Sale	6.76	50,676	342,626		Jun 06 04:11 PM
Alvino Mark	Director	May 27 '25	Sale	6.38	2,000	12,760	90,435	May 27 07:57 PM
Alvino Mark	Director	May 27 '25	Proposed Sale	6.38	2,000	12,762		May 27 04:40 PM
Alvino Mark	Director	May 16 '25	Sale	5.68	8,000	45,440	92,435	May 16 05:23 PM
Alvino Mark	Director	May 16 '25	Proposed Sale	5.68	8,000	45,423		May 16 04:07 PM
Seshadri Vishwas	Chief Executive Officer	Mar 31 '25	Sale	4.78	25,000	119,500	1,355,322	Mar 31 07:17 PM
Seshadri Vishwas	Officer	Mar 31 '25	Proposed Sale	4.78	25,000	119,560		Mar 31 04:08 PM

Open in Screener

RARE

Ultragenyx Pharmaceutical Inc

Feb 13 • 04:00PM ET

20.52

-2.98 -12.68 %

Healthcare • Biotechnology • USA • NASD

RARE Ultragenyx Pharmaceutical Inc daily Stock Chart

Peers: BIIB VRTX ALNY BMRN AMGN REGN IONS CRSP NBIX PBYI

| Held by: VTI XBI VB VBK VXF IBB IWP SCHA IWF IWR

Index	-	P/E	-	EPS (ttm)	-5.84	Insider Own	6.94%	Shs Outstand	96.48M	Perf Week	-16.92%
Market Cap	1.98B	Forward P/E	-	EPS next Y	-0.89	Insider Trans	-0.30%	Shs Float	89.85M	Perf Month	-14.75%
Enterprise Value	2.11B	PEG	-	EPS next Q	-1.37	Inst Own	99.73%	Short Float	10.12%	Perf Quarter	-38.80%
Income	-575.44M	P/S	2.94	EPS this Y	29.10%	Inst Trans	3.96%	Short Ratio	3.64	Perf Half Y	-29.27%
Sales	672.72M	P/B	215.68	EPS next Y	78.38%	ROA	-37.91%	Short Interest	9.10M	Perf YTD	-10.78%
Book/sh	0.10	P/C	2.69	EPS next 5Y	-	ROE	-656.54%	52W High	46.27 -55.65%	Perf Year	-52.85%
Cash/sh	7.64	P/FCF	-	EPS past 3/5Y	16.78% -13.72%	ROIC	-72.42%	52W Low	18.41 11.46%	Perf 3Y	-53.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	22.81% 19.95%	Gross Margin	83.85%	Volatility	7.56% 5.17%	Perf 5Y	-86.34%
Dividend TTM	-	EV/Sales	3.14	EPS Y/Y TTM	7.91%	Oper. Margin	-79.63%	ATR (14)	1.47	Perf 10Y	-62.53%
Dividend Ex-Date	-	Quick Ratio	1.74	Sales Y/Y TTM	20.08%	Profit Margin	-85.54%	RSI (14)	30.16	Recom	1.19
Dividend Gr. 3/5Y	- -	Current Ratio	1.89	EPS Q/Q	7.37%	SMA20	-13.77%	Beta	0.16	Target Price	56.05
Payout	-	Debt/Eq	-	Sales Q/Q	25.55%	SMA50	-25.38%	Rel Volume	2.88	Prev Close	23.50
Employees	1294	LT Debt/Eq	-	Earnings	Feb 12 AMC	SMA200	-34.52%	Avg Volume	2.50M	Price	20.52
IPO	Jan 31, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-18.07% 4.23%	Trades		Volume	7,194,308	Change	-12.68%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$65
Jul-28-25	Resumed	H.C. Wainwright	Buy	$80
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy	$56 → $67
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy	$162

Show Previous Ratings

Feb-14-26 01:29AM	Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A (Insider Monkey)
Feb-13-26 01:21PM	Why Is Ultragenyx Stock Sinking Friday? (Benzinga) -12.68%
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
08:30AM	Ultragenyx Pharmaceutical Inc. Q4 2025 Earnings Call Summary (Moby)
05:08AM	Ultragenyx cuts jobs as it seeks path to profit in 2027 (BioPharma Dive)
12:02AM	Loading…
12:02AM	Ultragenyx Pharmaceutical Inc (RARE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Feb-12-26 08:14PM	Ultragenyx Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
06:00PM	Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:18PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update (GlobeNewswire)
Feb-09-26 03:30AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Feb-07-26 03:33AM	Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment (Insider Monkey)
Feb-06-26 07:40AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights RARE (Business Wire)
Feb-05-26 04:05PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Loading…
10:00AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-03-26 12:58PM	Ultragenyx Says Gene Therapy Shows Lasting Benefits, Slows Brain Decline In Fatal Childhood Disorder (Benzinga)
08:00AM	Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) (GlobeNewswire)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
Jan-30-26 08:30AM	Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA (GlobeNewswire)
Jan-23-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:05PM	Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies (PR Newswire)
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
Jan-12-26 10:11AM	Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery (Insider Monkey) +8.26%
07:30AM	Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference (GlobeNewswire)
Jan-09-26 03:16AM	Analysts Lower Ultragenyx (RARE) Target but Stay Bullish (Insider Monkey)
Jan-07-26 04:05PM	Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.36%
Jan-05-26 03:56AM	Novo launches Wegovy pill; Argenx to swap CEOs (BioPharma Dive)
Dec-31-25 09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)
09:40AM	DigitalBridge downgraded, Commvault initiated: Wall Streets top analyst calls (TipRanks)
09:01AM	Loading…
09:01AM	Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? (Zacks)
07:37AM	Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall (Insider Monkey)
Dec-30-25 04:31PM	Stocks Fall Slightly in Thin Holiday Trade (Barchart) +15.52%
04:05PM	Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
03:58PM	Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today (Motley Fool)
12:39PM	Why Ultragenyx Stock Dropped 42% and What Comes Next (Barrons.com)
11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
09:36AM	DigitalBridge downgraded, Commvault initiated: Wall Street's top analyst calls (The Fly)
08:11AM	Company News for Dec 30, 2025 (Zacks)
06:17AM	S&P Futures Tread Water Ahead of FOMC Meeting Minutes (Barchart)
Dec-29-25 04:21PM	These Stocks Moved the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More (Barrons.com) -42.32%
03:34PM	Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today (Motley Fool)
01:18PM	These Stocks Are Moving the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More (Barrons.com)
01:05PM	These biotech stocks are getting hammered by shocking brittle-bone treatment study results (MarketWatch)
08:30AM	Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta (GlobeNewswire)
Dec-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-11-25 07:44AM	Is Ultragenyx Pharmaceutical Inc. (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Dec-04-25 11:30AM	Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-28-25 11:57AM	Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook (Insider Monkey)
Nov-24-25 04:30PM	Ultragenyx to Participate in Investor Conferences in December (GlobeNewswire)
Nov-21-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.73%
Nov-10-25 08:19PM	Morgan Stanley Reaffirms "Buy" Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT (Insider Monkey)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
12:10AM	Ultragenyx Pharmaceutical Inc (RARE) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-04-25 05:30PM	Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 Earnings (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
04:01PM	Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita (burosumab) for $400 Million to OMERS Life Sciences (GlobeNewswire)
Oct-30-25 08:00AM	Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups (GlobeNewswire)
Oct-29-25 10:00AM	Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-28-25 04:30PM	Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-24-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.31%
Oct-17-25 09:16AM	Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength? (Zacks)
Oct-08-25 12:57AM	Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Oct-03-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-25 09:45AM	Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline (Insider Monkey)
Sep-30-25 04:05PM	Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President (GlobeNewswire)
04:00AM	Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Sep-29-25 08:28AM	FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza (Zacks)
Sep-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-25 09:17AM	Is Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity? (Insider Monkey)
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)
Sep-08-25 04:05PM	Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Aug-29-25 04:30PM	Ultragenyx to Participate at Investor Conferences in September (GlobeNewswire) +6.91%
Aug-21-25 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-18-25 08:00AM	Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Aug-06-25 11:43AM	Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
03:29AM	Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Aug-05-25 05:30PM	Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:06PM	Ultragenyx: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Aug-04-25 03:32PM	Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory (Insider Monkey)
Jul-31-25 04:05PM	Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome (GlobeNewswire)
11:35AM	Ultragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick Resubmission (Insider Monkey)
10:00AM	Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline (Zacks)
Jul-30-25 08:30AM	Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Jul-24-25 11:09AM	BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Jul-22-25 10:05AM	FDA Rejects Replimunes Skin Cancer Treatment, Shares Sink (Bloomberg)
Jul-18-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-17-25 10:38AM	Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Jul-16-25 09:38AM	William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
07:00AM	New Pedestrian Access from Inner Belt to East Somerville MBTA Station Now Open to the Public (PR Newswire)
Jul-15-25 08:28AM	Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA (Zacks) -6.94%
05:46AM	Health Canada extends Evkeeza approval for children with HoFH (Pharmaceutical Technology)
Jul-14-25 04:24PM	Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection (Investor's Business Daily)
08:00AM	Health Canada Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Horn Howard	Chief Financial Officer	Feb 02 '26	Sale	23.56	3,061	72,117	88,935	Feb 03 12:00 PM
HOWARD HORN	Officer	Feb 02 '26	Proposed Sale	23.56	3,061	72,117		Feb 02 04:09 PM
Horn Howard	Chief Financial Officer	Jan 02 '26	Sale	22.84	3,150	71,946	91,996	Jan 05 04:07 PM
HOWARD HORN	Officer	Jan 02 '26	Proposed Sale	22.84	3,150	71,946		Jan 02 04:10 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Dec 29 '25	Sale	34.38	85	2,922	50,450	Dec 30 01:49 PM
Horn Howard	Chief Financial Officer	Dec 10 '25	Sale	36.38	3,081	112,087	95,146	Dec 11 12:10 PM
HOWARD HORN	Officer	Dec 10 '25	Proposed Sale	36.38	3,081	112,087		Dec 10 04:05 PM
Horn Howard	Chief Financial Officer	Oct 13 '25	Sale	31.51	7,942	250,252	98,227	Oct 14 12:15 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 18 '25	Sale	29.17	64	1,867	50,242	Sep 19 06:23 PM
KARAH PARSCHAUER	Officer	Sep 12 '25	Proposed Sale	31.17	2,450	76,366		Sep 12 04:17 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Sep 12 '25	Sale	31.17	2,450	76,366	73,271	Sep 12 04:11 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 05 '25	Sale	31.39	84	2,637	50,306	Sep 08 02:01 PM
Sanders Corazon (Corsee) D.	Director	Jun 20 '25	Sale	37.39	2,405	89,923	15,344	Jun 23 01:50 PM
CORAZON D. SANDERS	Director	Jun 20 '25	Proposed Sale	37.39	2,405	89,923		Jun 20 04:02 PM
Crombez Eric	EVP and Chief Medical Officer	May 05 '25	Sale	39.24	520	20,405	71,530	May 05 07:18 PM
Crombez Eric	EVP and Chief Medical Officer	Apr 21 '25	Sale	35.11	242	8,497	71,680	May 05 07:18 PM
Horn Howard	Chief Financial Officer	Mar 06 '25	Sale	40.40	1,785	72,114	106,169	Mar 10 12:53 PM
Kassberg Thomas Richard	CBO & EVP	Mar 03 '25	Sale	42.10	6,028	253,779	265,238	Mar 04 08:19 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 03 '25	Sale	42.10	12,846	540,817	75,287	Mar 04 08:18 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 03 '25	Sale	42.10	8,945	376,584	71,922	Mar 04 08:16 PM
Pinion John Richard	See Remarks	Mar 03 '25	Sale	42.10	14,439	607,882	107,766	Mar 04 08:12 PM
KAKKIS EMIL D	President & CEO	Mar 03 '25	Sale	42.10	73,434	3,091,571	641,731	Mar 04 08:10 PM
KAKKIS EMIL D	President & CEO	Feb 28 '25	Sale	42.48	25,000	1,062,000	2,158,985	Mar 04 08:10 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 03 '25	Sale	42.10	15,103	635,836	87,855	Mar 04 08:06 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 03 '25	Sale	42.10	967	40,711	50,265	Mar 04 08:00 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Feb 27 '25	Sale	42.88	2,990	128,224	54,991	Mar 03 01:58 PM
KAKKIS EMIL D	Officer	Feb 28 '25	Proposed Sale	42.48	25,000	1,062,100		Feb 28 04:11 PM
Parschauer Karah Herdman	Officer	Feb 27 '25	Proposed Sale	42.88	2,990	128,215		Feb 27 05:08 PM

ABEO

Abeona Therapeutics Inc

RARE

Ultragenyx Pharmaceutical Inc

Upgrade your FINVIZ experience